Fasting Triggers a Brain-Boosting Molecule Called BDNF. The Science Is Promising But Incomplete

When you fast, your body does not simply run low on fuel. It switches metabolic gears, and some of those gears appear to turn inside the brain itself. A new review published in Nutrition Reviews traces a molecular chain from fasting-induced metabolic changes to a protein called brain-derived neurotrophic factor (BDNF) and onward to neuroplasticity, the brain's capacity to reorganize and strengthen its own circuits. The findings are genuinely interesting. They are also, by the authors' own account, preliminary: most of the compelling mechanistic evidence comes from animal studies, and human data remain limited and heterogeneous.

BDNF Acts as a Molecular Crossroads Between Metabolism and the Brain

BDNF sits at an unusual intersection. It is best known as a growth factor for neurons, supporting their survival and the remodeling of synapses. But the review describes it as something broader: a context-dependent signal that links the body's energy status with the brain's capacity to adapt. On the neurotrophic side, mature BDNF binds the TrkB receptor to promote neuronal survival and synaptic strengthening. Its precursor form, proBDNF, does the opposite, binding the p75NTR receptor to weaken and retract synapses. The ratio between the two matters as much as the total amount.

On the metabolic side, BDNF does more than most people realize. It increases neuronal glucose uptake by upregulating glucose transporters GLUT1 and GLUT3. It helps maintain insulin-producing beta cells in the pancreas and potentiates glucose-stimulated insulin secretion. Through the BDNF/TrkB/CREB pathway, it suppresses hepatic gluconeogenesis, improves leptin sensitivity, and reduces food intake. Circulating BDNF levels are consistently reduced in people with type 2 diabetes, a pattern that hints at a bidirectional relationship between metabolic dysfunction and impaired neurotrophic signaling. Dietary interventions that address metabolic risk factors, including those targeting insulin resistance and related conditions, may therefore have neurological consequences that researchers are only beginning to map.

How Fasting Shifts the Metabolic Environment That BDNF Needs

The link between fasting and BDNF is not direct. It runs through ketone bodies, particularly beta-hydroxybutyrate (BHB), the molecule your liver produces in meaningful quantities after roughly 24 to 72 hours without eating. BHB upregulates BDNF expression in neuronal tissues, and it does so partly by activating AMPK and SIRT1, two cellular energy-sensing enzymes that together create what the review calls a permissive context for BDNF signaling. The AMPK/SIRT1 axis also drives mitochondrial biogenesis, which matters because healthy mitochondria are essential infrastructure for active neurons.

The review notes a threshold-dependent pattern: higher and more prolonged increases in circulating BHB are associated with delayed increases in peripheral proBDNF. This is not a smooth dose-response curve; it suggests the system activates only when metabolic shifts pass a certain magnitude, which has practical implications for how long or how deep a fast needs to be to produce neurobiological effects. Periodic short-term fasting of up to 72 hours appears safe for mood in existing studies, with transient increases in depressive scores likely reflecting physiological stress responses rather than genuine affective deterioration.

Interestingly, adiponectin, a hormone released by fat tissue, also connects to BDNF: adiponectin signaling promotes BDNF expression and may be one route through which improved metabolic health, of the kind associated with dietary patterns that reduce cardiometabolic risk, feeds back into neuroplasticity.

Human Evidence on Fasting and BDNF Remains Frustratingly Mixed

Here is where the review is most useful as a reality check. Preclinical work, mostly rodent studies, shows reasonably consistent increases in BDNF following intermittent fasting or caloric restriction. The human picture is messier. Circulating BDNF levels in people who fast vary considerably across studies, shaped by baseline metabolic health, the specific fasting protocol used, how long fasting lasted, and individual genetic differences.

One such difference is the BDNF rs6265 polymorphism, known as Val66Met, which alters the intracellular trafficking of BDNF and impairs activity-dependent secretion. Carriers of this variant may simply not release BDNF efficiently in response to the same stimuli. The review also highlights a deeper measurement problem: peripheral BDNF in the blood does not reliably reflect central BDNF in the brain. Platelets store and release BDNF, which means that blood levels are influenced by factors unrelated to brain neurotrophic activity. Changes in circulating BDNF may instead reflect broader psychometabolic and inflammatory adaptations. Researchers relying on rigorous risk-of-bias standards in nutritional science have increasingly flagged exactly this kind of biomarker-interpretation problem.

The review also examines electroencephalography (EEG) as a potential systems-level readout of neuroplastic changes: gamma-range oscillations and cross-frequency coupling are associated with learning and synaptic adaptation. The hypothesis is that fasting-induced changes in BDNF dynamics could plausibly alter the brain's oscillatory organization. But the authors are candid: direct evidence linking EEG dynamics to BDNF modulation in humans is limited and largely correlational. Observed EEG shifts may reflect changes in arousal or cognitive effort rather than actual synaptic remodeling.

Key Gaps That Future Research Needs to Fill

The review's clearest contribution may be the research agenda it lays out. No large-scale randomized controlled trials have combined electrophysiological measures like EEG with biomarkers of central neuroplasticity and behavioral outcomes in the same fasting intervention study. Most existing studies have small sample sizes, inconsistent fasting protocols, and mixed populations that are rarely stratified by sex, even though sex-specific differences in BDNF responses are plausible.

The authors also flag a sociocultural complication: clinical and public health settings tend to treat extended fasting with caution, which limits the scope of medically supervised protocols that researchers can realistically propose and get approved. Separating fasting effects from exercise effects is another challenge, since physical activity is itself a well-established driver of BDNF signaling and many people who fast also exercise.

The direction the review points toward is multimodal: future studies should combine neurotrophic markers, EEG readouts, behavioral and affective outcomes, and metabolic profiling within the same design, and they should stratify by genetic variants like Val66Met. Precision frameworks that match interventions to individual metabolic and genetic profiles, an approach gaining traction in nutritional science more broadly, may eventually clarify which people stand to gain the most from fasting-based strategies targeting brain health.

For now, the honest summary is this: fasting likely shifts the molecular environment in ways that are favorable for neuroplasticity, with BHB and BDNF as plausible intermediaries. Whether those shifts translate into measurable cognitive or psychiatric benefits in humans, and in which humans, remains an open question. The hypothesis is well-constructed. The evidence to test it rigorously, in people, does not yet exist.

Evidence rating

INVESTIGATIONAL — 61/100

Caveats:

• This is a narrative review, not a clinical trial — it synthesizes existing literature rather than generating new experimental data.
• Human data on fasting and circulating BDNF are limited, heterogeneous, and do not establish causation.
• Most mechanistic evidence comes from preclinical (animal) models and cannot be directly extrapolated to humans.
• Peripheral (blood) BDNF measurements may not reflect central (brain) neurotrophic signaling.
• Funding was not disclosed by the authors.

Narrative review synthesizing preclinical and limited human literature on fasting-induced BDNF modulation and neuroplasticity. No original data are presented; human findings are described as heterogeneous and inconclusive, with causal links between fasting, circulating BDNF, and central neuroplastic outcomes not established. Not yet supported by controlled longitudinal trials in humans.

References

1. Karolina Kapłon, Marta Napiórkowska-Mastalerz, Aelita Bredelytė, Barbara Ciastek (2026). Brain-Derived Neurotrophic Factor as a Molecular Bridge Between Fasting, Neuroplasticity, and Metabolic Regulation: Clinical and Translational Insights. Nutrition Reviews. https://doi.org/10.1093/nutrit/nuag089
2. Christina A. Chatzi, Athanasios Basios, Georgios Markozannes, et al. (2024). Effect of Different Dietary Patterns on Cardiometabolic Risk Factors: An Umbrella Review of Systematic Reviews and Meta-Analyses. Nutrients. https://doi.org/10.3390/nu16223873
3. Neha J. Pagidipati, Pam R. Taub, Robert J. Ostfeld, Carol F. Kirkpatrick (2024). Dietary patterns to promote cardiometabolic health. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-024-01061-7
4. Lukas Schwingshackl, Holger J. Schünemann, Joerg J. Meerpohl (2020). Improving the trustworthiness of findings from nutrition evidence syntheses: assessing risk of bias and rating the certainty of evidence. European Journal of Nutrition. https://doi.org/10.1007/s00394-020-02464-1
5. Guy Vergères, Murielle Bochud, Corinne Jotterand Chaparro, et al. (2024). The future backbone of nutritional science: integrating public health priorities with system-oriented precision nutrition. British Journal of Nutrition. https://doi.org/10.1017/s0007114524001466